Drugs / MT2004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06019936 | Aug 2023 → Aug 2025 | cholestasis, drug-induced liver injury | Xi'An Aolitai Pharmaceutical Technology Co Ltd | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04277910 Comparator | Jan 2020 → Apr 2021 | — | Xi'an Biocare Pharma Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT2004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06019936 ↗ |
| Action | Activate | “Xi'An Aolitai Pharmaceutical Technology Co Ltd is developing MT2004, a novel investigational synthetic small molecule farnesoid X receptor (FXR) agonist targeted to the liver.” NCT06019936 ↗ |
| Modality | Small molecule | “novel investigational synthetic small molecule farnesoid X receptor (FXR) agonist” NCT06019936 ↗ |
| Route | Oral | “MT2004 oral capsules” NCT04277910 ↗ |